Stock Scorecard



Stock Summary for Polypid Ltd (PYPD) - $2.79 as of 5/3/2025 8:36:49 AM EST

Total Score

9 out of 30

Safety Score

11 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PYPD

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PYPD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PYPD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PYPD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PYPD (11 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 0
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for PYPD

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 4/29/2025 11:00:00 AM
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - PolyPid ( NASDAQ:PYPD ) 4/29/2025 11:00:00 AM
PolyPid to Participate in The Citizens Life Sciences Conference - PolyPid ( NASDAQ:PYPD ) 4/22/2025 11:00:00 AM
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - PolyPid ( NASDAQ:PYPD ) 3/11/2025 11:00:00 AM
PolyPid to Participate in the 37th Annual ROTH Conference - PolyPid ( NASDAQ:PYPD ) 3/3/2025 12:00:00 PM
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference 1/30/2025 12:00:00 PM
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 - PolyPid ( NASDAQ:PYPD ) 1/29/2025 12:00:00 PM
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 1/29/2025 12:00:00 PM
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday - ACV Auctions ( NASDAQ:ACVA ) , Anavex Life Sciences ( NASDAQ:AVXL ) 12/26/2024 3:31:00 PM
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - PolyPid ( NASDAQ:PYPD ) 12/24/2024 12:22:00 AM

Financial Details for PYPD

Company Overview

Ticker PYPD
Company Name Polypid Ltd
Country USA
Description PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Sector Name LIFE SCIENCES
Industry Name SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/6/2025

Stock Price History

Last Day Price 2.79
Price 4 Years Ago 172.20
Last Day Price Updated 5/3/2025 8:36:49 AM EST
Last Day Volume 4,018
Average Daily Volume 14,160
52-Week High 4.94
52-Week Low 2.30
Last Price to 52 Week Low 21.30%

Valuation Measures

Trailing PE N/A
Industry PE 50.99
Sector PE 37.03
5-Year Average PE -17.44
Free Cash Flow Ratio 1.82
Industry Free Cash Flow Ratio 41.76
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 1.31
Total Cash Per Share 1.53
Book Value Per Share Most Recent Quarter 0.75
Price to Book Ratio 3.70
Industry Price to Book Ratio 5.32
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 4.31
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 10,190,900
Market Capitalization 28,432,611
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -21.61%
Reported EPS 12 Trailing Months -4.91
Reported EPS Past Year 0.00
Reported EPS Prior Year -4.91
Net Income Twelve Trailing Months -29,022,000
Net Income Past Year -29,022,000
Net Income Prior Year -23,865,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 15,641,000
Total Cash Past Year 15,641,000
Total Cash Prior Year 5,609,000
Net Cash Position Most Recent Quarter 15,007,000
Net Cash Position Past Year 15,007,000
Long Term Debt Past Year 634,000
Long Term Debt Prior Year 6,379,000
Total Debt Most Recent Quarter 634,000
Equity to Debt Ratio Past Year 0.92
Equity to Debt Ratio Most Recent Quarter 0.92
Total Stockholder Equity Past Year 7,684,000
Total Stockholder Equity Prior Year -2,096,000
Total Stockholder Equity Most Recent Quarter 7,684,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 0
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year -22,039,000
Free Cash Flow Prior Year -17,432,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.02
MACD Signal -0.02
20-Day Bollinger Lower Band 2.46
20-Day Bollinger Middle Band 2.92
20-Day Bollinger Upper Band 3.39
Beta 1.28
RSI 51.67
50-Day SMA 20.93
150-Day SMA 0.00
200-Day SMA 63.84

System

Modified 5/3/2025 8:36:50 AM EST